Telos Capital Management Inc. Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Telos Capital Management Inc. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 301 shares of the biopharmaceutical company’s stock after selling 41 shares during the quarter. Telos Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $214,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Financial Advocates Investment Management bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $474,000. Private Wealth Management Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares in the last quarter. Tectonic Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 16.6% during the fourth quarter. Tectonic Advisors LLC now owns 830 shares of the biopharmaceutical company’s stock worth $591,000 after purchasing an additional 118 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Regeneron Pharmaceuticals by 21.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 55,426 shares of the biopharmaceutical company’s stock worth $38,305,000 after purchasing an additional 9,845 shares in the last quarter. Finally, Paragon Capital Management Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at about $1,257,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.7 %

Regeneron Pharmaceuticals stock opened at $710.00 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The stock has a market cap of $78.02 billion, a price-to-earnings ratio of 17.57, a PEG ratio of 1.60 and a beta of 0.08. The company’s 50-day moving average price is $716.62 and its two-hundred day moving average price is $913.59. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company posted $11.86 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.50%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on REGN. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Oppenheimer lowered their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $762.00 to $834.00 in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.